DCPH vs. KROS, AMPH, RCKT, AMRX, ARDX, EWTX, SNDX, NAMS, MRVI, and GLPG
Should you be buying Deciphera Pharmaceuticals stock or one of its competitors? The main competitors of Deciphera Pharmaceuticals include Keros Therapeutics (KROS), Amphastar Pharmaceuticals (AMPH), Rocket Pharmaceuticals (RCKT), Amneal Pharmaceuticals (AMRX), Ardelyx (ARDX), Edgewise Therapeutics (EWTX), Syndax Pharmaceuticals (SNDX), NewAmsterdam Pharma (NAMS), Maravai LifeSciences (MRVI), and Galapagos (GLPG). These companies are all part of the "pharmaceutical preparations" industry.
Deciphera Pharmaceuticals (NASDAQ:DCPH) and Keros Therapeutics (NASDAQ:KROS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, community ranking, risk and media sentiment.
Keros Therapeutics has lower revenue, but higher earnings than Deciphera Pharmaceuticals. Deciphera Pharmaceuticals is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Keros Therapeutics had 3 more articles in the media than Deciphera Pharmaceuticals. MarketBeat recorded 12 mentions for Keros Therapeutics and 9 mentions for Deciphera Pharmaceuticals. Keros Therapeutics' average media sentiment score of 0.87 beat Deciphera Pharmaceuticals' score of -0.05 indicating that Keros Therapeutics is being referred to more favorably in the news media.
Deciphera Pharmaceuticals currently has a consensus price target of $24.17, indicating a potential downside of 4.69%. Keros Therapeutics has a consensus price target of $86.00, indicating a potential upside of 58.47%. Given Keros Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Keros Therapeutics is more favorable than Deciphera Pharmaceuticals.
71.0% of Deciphera Pharmaceuticals shares are held by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are held by institutional investors. 4.4% of Deciphera Pharmaceuticals shares are held by insiders. Comparatively, 22.9% of Keros Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Keros Therapeutics has a net margin of 0.00% compared to Deciphera Pharmaceuticals' net margin of -119.33%. Deciphera Pharmaceuticals' return on equity of -49.44% beat Keros Therapeutics' return on equity.
Deciphera Pharmaceuticals received 280 more outperform votes than Keros Therapeutics when rated by MarketBeat users. However, 66.67% of users gave Keros Therapeutics an outperform vote while only 64.91% of users gave Deciphera Pharmaceuticals an outperform vote.
Deciphera Pharmaceuticals has a beta of 0.2, indicating that its share price is 80% less volatile than the S&P 500. Comparatively, Keros Therapeutics has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500.
Summary
Keros Therapeutics beats Deciphera Pharmaceuticals on 13 of the 18 factors compared between the two stocks.
Get Deciphera Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for DCPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DCPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Deciphera Pharmaceuticals Competitors List
Related Companies and Tools
